QHSLab, Inc. Reports 127% Year-Over-Year ISP Revenue Growth and Launches Q-Connect GLP-1 Support Assessment
Key Highlights from Q1 2026 Report
- Q1 2026 ISP Revenue Soars: QHSLab, Inc. (OTCQB: USAQ) generated unaudited Integrated Service Program (ISP) revenue of approximately \$370,000 in Q1 2026, a 127% increase from \$163,000 in Q1 2025. This \$207,000 year-over-year growth is a strong indicator of the company’s expanding provider base and growing adoption of its recurring digital care model among primary care and specialty practices.
- Platform Expansion: The growth was supported by increasing provider adoption, the launch of the Q-Connect AOM and GLP-1 Support Assessment, and ongoing development of personalized cardiometabolic health journeys. The company’s platform now extends into metabolic and behavioral health, aiming to strengthen patient engagement and expand recurring care opportunities.
- Launch of Q-Connect GLP-1 Support Assessment: QHSLab announced the launch of Q-Connect GLP-1, a new assessment and health journeys program tailored to support patients using anti-obesity medications (AOMs), including GLP-1 therapies, as well as individuals aiming to improve overall cardiometabolic health, quality of life, and daily functioning.
Details and Strategic Insights
QHSLab’s ISP platform is designed to enable medical practices to identify, monitor, and support patients across a range of chronic and behavioral health conditions using digital assessments, structured reporting, and ongoing engagement that extends beyond traditional office visits. This model is closely aligned with existing reimbursement pathways, reducing workflow burdens for providers while helping them document and receive appropriate compensation for care delivered outside of standard appointments.
CEO Troy Grogan commented, “This level of growth reflects what we are seeing in the field every day. Practices are looking for practical ways to deliver better care, document what they are already doing, and be appropriately reimbursed. Our platform is designed to fit into that reality without adding complexity.”
The newly launched Q-Connect GLP-1 program responds to the growing use of anti-obesity medications. According to Dr. Marcos Sanchez-Gonzalez, Vice President of Scientific and Medical Affairs, “GLP-1 medications are an important tool, but they are only one part of the equation. Patients experience changes that go beyond weight, including sleep, mood, stress, daily habits, and cardiometabolic factors. Q-Connect GLP-1 helps patients understand and manage those changes in a structured and scalable way.” Board-certified endocrinologist Dr. Reza Yavari further emphasized that real-world outcomes are improved when patients receive structured lifestyle support, and Q-Connect aims to close the gap in monitoring day-to-day adaptation to therapy.
The Q-Connect assessment is designed to integrate into existing clinical workflows and can be deployed before, during, or after visits as part of ongoing population health strategies. Importantly, Q-Connect also supports broader patient populations interested in lifestyle improvement beyond GLP-1 medication use.
“With Q-Connect, we continue to build on our core infrastructure approach,” Grogan added. “This is about helping practices deliver consistent, measurement-based care across conditions, while creating a better experience for patients and providers.”
The Q-Connect GLP-1 Support Assessment and Personalized Health Journeys Program is now available to QHSLab partner practices nationwide.
About QHSLab
QHSLab, Inc. is a digital health infrastructure company enabling independent primary care practices with workflow-integrated digital screening, clinical decision support, and care management services. The platform is specifically designed to help physicians identify and manage underdiagnosed behavioral health and chronic conditions, supporting reimbursable clinical activities both during and beyond traditional office visits. Revenue is generated mainly through recurring service fees from participating medical practices. QHSLab also operates an allergy diagnostics and treatment service line under the AllergiEnd® brand.
For additional information, investors may visit the company’s website at QHSLab Investor Relations.
Potential Price-Sensitive Information for Shareholders
- Exceptional Revenue Growth: The 127% year-over-year surge in ISP revenue is a direct signal of increasing market traction and could influence investor sentiment and share value positively.
- Product Launch: The nationwide rollout of the Q-Connect GLP-1 Support Assessment program positions QHSLab at the forefront of the fast-growing digital and metabolic health management space, an area of high investor interest.
- Ongoing Innovation: The company’s commitment to expanding into behavioral and cardiometabolic health, and its structured, scalable approach to supporting patients on GLP-1 therapies, could differentiate it from competitors and open new revenue streams.
- Scalable Recurring Revenue Model: With revenue primarily from recurring service fees, QHSLab’s model supports sustainable growth and visibility for future results.
Forward-Looking Statements and Disclaimer
Certain statements in this article are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include, but are not limited to, timing of new product introductions, regulatory changes, overall economic conditions, and other factors not within the company’s control. Investors should review filings with the Securities and Exchange Commission for a fuller discussion of risks and uncertainties. This article is for informational purposes only and does not constitute investment advice.
View QHSLab, Inc. Historical chart here
